Creative Planning Lineage Cell Therapeutics, Inc. Transaction History

Creative Planning

$101 Billion
Q3 2024

A detailed history of Creative Planning transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Creative Planning holds 24,172 shares of LCTX stock, worth $20,787. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,172

Previous 24,172 -0.0%

Holding current value

$20,787

Previous $24,000 12.5%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$0.89 - $1.47 $1,716 - $2,835	-1,929 Reduced 7.39%	24,172 $24,000
Q4 2023 Feb 14, 2024	SELL	$0.91 - $1.35 $1,767 - $2,621	-1,942 Reduced 6.93%	26,101 $28,000
Q3 2023 Nov 16, 2023	SELL	$1.16 - $1.53 $3,303 - $4,357	-2,848 Reduced 9.22%	28,043 $33,000
Q1 2023 May 15, 2023	BUY	$1.2 - $1.53 $5,520 - $7,038	4,600 Added 17.5%	30,891 $46,000
Q4 2022 Feb 10, 2023	SELL	$1.02 - $1.5 $78 - $115	-77 Reduced 0.29%	26,291 $30,000
Q3 2022 Nov 03, 2022	BUY	$1.13 - $1.77 $74 - $116	66 Added 0.25%	26,368 $30,000
Q2 2022 Aug 15, 2022	BUY	$1.12 - $1.61 $807 - $1,160	721 Added 2.82%	26,302 $42,000
Q1 2022 May 16, 2022	BUY	$1.21 - $2.48 $2,420 - $4,960	2,000 Added 8.48%	25,581 $39,000
Q4 2021 Feb 11, 2022	SELL	$1.84 - $2.68 $3,637 - $5,298	-1,977 Reduced 7.74%	23,581 $58,000
Q3 2021 Nov 10, 2021	BUY	$2.26 - $2.86 $1,261 - $1,595	558 Added 2.23%	25,558 $64,000
Q2 2021 Aug 04, 2021	SELL	$2.17 - $3.0 $198,453 - $274,359	-91,453 Reduced 78.53%	25,000 $71,000
Q4 2020 Jan 29, 2021	SELL	$0.95 - $1.83 $0 - $1	-1 Reduced -0.0%	116,453 $205,000
Q3 2020 Nov 05, 2020	SELL	$0.75 - $1.09 $16,682 - $24,244	-22,243 Reduced 16.04%	116,454 $109,000
Q2 2020 Jul 23, 2020	BUY	$0.71 - $1.18 $23,842 - $39,625	33,581 Added 31.95%	138,697 $121,000
Q1 2020 May 05, 2020	SELL	$0.6 - $1.58 $50,550 - $133,116	-84,251 Reduced 44.49%	105,116 $87,000
Q4 2019 Jan 30, 2020	SELL	$0.54 - $1.01 $8,540 - $15,973	-15,815 Reduced 7.71%	189,367 $169,000
Q3 2019 Nov 01, 2019	BUY	$0.85 - $1.24 $174,404 - $254,425	205,182 New	205,182 $201,000

Others Institutions Holding LCTX

# of Institutions

122

Shares Held

94.3M

Call Options Held

63.8K

Put Options Held

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $146M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.

Account

Creative Planning Lineage Cell Therapeutics, Inc. Transaction History